Natixis Advisors LLC Buys New Position in Insmed Incorporated (NASDAQ:INSM)

Natixis Advisors LLC purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 20,894 shares of the biopharmaceutical company’s stock, valued at approximately $1,525,000.

Other hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its position in shares of Insmed by 8.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 135 shares in the last quarter. CIBC Asset Management Inc increased its stake in Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 149 shares during the last quarter. CWM LLC lifted its position in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares in the last quarter. GAMMA Investing LLC lifted its position in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on INSM. TD Cowen lifted their target price on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com cut Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Bank of America raised their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Finally, UBS Group lifted their price objective on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insider Activity at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 27.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The trade was a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Insmed Trading Up 1.3 %

Shares of NASDAQ:INSM opened at $74.09 on Tuesday. The stock has a market cap of $13.25 billion, a PE ratio of -13.18 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The business has a 50 day moving average of $72.04 and a 200-day moving average of $66.60.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.10) earnings per share. As a group, equities research analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.